Biosimilars usa
AXINN, VELTROP & HARKRIDER LLP © 2007 | AXINN, VELTROP & HARKRIDER LLP Click To Modify Title Name Goes Here FDA Hearings on the BPCI Act.
Biosimilars webinar April 2015
Pharma and Biotech Industry Outlook - A look at trends and opportunities in this increasingly challenging environment with a focus on the generics landscape
E NGEL & N OVITT, LLP T HE L AW F IRM T HAT K NOWS I TS S CIENCE © E&N LLP US Regulatory Pathway For Biosimilars Practical Legal/Regulatory Considerations.
1 CBER Rare Diseases Program - Update 2011-2012 Nisha Jain, MD Chief, Clinical Review Branch DH/OBRR/CBER/FDA May 15, 2012 NORD Corporate Council.
New York Washington Seattle Brian J. Malkin, Partner ([email protected]) Brian J. Malkin, Partner ([email protected])[email protected] Frommer Lawrence.
1 Kansas Bio “Hot Topics In Science” April 1, 2010 “Key Life Science Provisions of the Healthcare Act of 2010”
Why aren’t Biosimilars Generics – Regulatory Challenges Adam Sabouni, PhD PharmaConsultz 4 th International Conference on Pharmaceutical Regulatory Affairs.
Safe Substitution of Biologics
A New Pathway for Follow-on Biologics Presented by: Steve Nash [email protected] May 7, 2010.
1 AbbVie, Inc. Date: 12 November 2013 Jing Chen Hisham Haider Dewan Harout Sahakian.
